Presentation Materials for the Briefing on the Results for the Fiscal Year Ended June 2025 | Human Metabolome Technologies,Inc. (6090) timely disclosure

Worth reading

51Recurring

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Mixed performance

Direction inferred from the company’s description.

Scale

109

¥ million

Wording

Conditional

How definitive the wording is.

Contents of this document

Presentation materials for financial resultsFiscal year ended June 202511 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales¥1,455 million+8.1%

Operating profit¥249 million+13.3%

Ordinary income¥240 million-0.2%

Net income¥256 million+5.4%

Full-year earnings forecast

Net Sales

¥1,600 million

Operating profit

¥300 million

Ordinary income

¥300 million

Profit attributable to owners of the parent

¥260 million

Dividend per share

¥18

What the company explained in this material

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

先端研究開発支援事業利益売上減少、売上減少に伴う原価減少、バイオものづくり支援サービスへの研究開発投資、人件費増加、貸倒引当

ヘルスケア・ソリューション事業利益機能性素材開発包括支援サービス・皮膚ガス測定の売上増加、売上増加に伴う原価増加、研究開発投資の先端研究開発支援事業へのシフト

Consolidated operating profit

売上総利益増加額¥52 million

New initiatives

Segment integration
バイオものづくり支援サービスの開始・早期立ち上げ
ペプチドスキャンアドバンスト、糖分析オプションの発売開始
自社株式取得の検討

Key KPIsA metric the company considers important as a management benchmark.

12期連続増収Yes

5期連続営業増益Yes

新サービス受注

¥13 million

Overseas business revenue

-56 %

Year on year against the same period last yearYear-on-year

ROE

Fiscal year ended June 202513.6 %

WACC

Fiscal year ended June 20253-5%

Year on year against the same period last yearDown

Cost of shareholders’ equity

Fiscal year ended June 20254-6%

Year on year against the same period last yearDown

PBR

Fiscal year ended June 20252.4 times

PER

Fiscal year ended June 202517.5 times

Segment results

Advanced research and development support business

Net Sales

Fiscal year ended June 2024¥1,186 million

Fiscal year ended June 2025¥1,143 million

Change in amount¥-43 million

Cost

Fiscal year ended June 2024¥876 million

Fiscal year ended June 2025¥958 million

Change in amount¥82 million

Profit

Fiscal year ended June 2024¥310 million

Fiscal year ended June 2025¥184 million

Change in amount¥-126 million

Healthcare solutions business

Net Sales

Fiscal year ended June 2024¥158 million

Fiscal year ended June 2025¥311 million

Change in amount¥153 million

Cost

Fiscal year ended June 2024¥249 million

Fiscal year ended June 2025¥247 million

Change in amount¥-2 million

Profit

Fiscal year ended June 2024¥-90 million

Fiscal year ended June 2025¥64 million

Change in amount¥155 million

Medium-term management plan targets

Net Sales

Fiscal year ending June 2026¥1,600 million

Operating profit

Fiscal year ending June 2026¥300 million

Ordinary income

Fiscal year ending June 2026¥300 million

Profit attributable to owners of the parent

Fiscal year ending June 2026¥260 million

Financial targets

ROE target中長期的に15%以上

Actual ROE2025年6月期13.6%

Number of employees

Number of Employees62 People

博士11 People

Reference dateJune 2025

Capital expenditures

5 億円M&A・設備投資などの戦略投資資金

Annual Dividend

Fiscal year ended June 2025

¥15

Forecast for the fiscal year ending June 2026

¥18

Payout ratio

2026年6月期40%程度

Acquisition of treasury shares

実施中の自社株購入結果および中間決算の状況を踏まえ、自社株式取得を検討

Contents of this document
Item	Details
Document type	Presentation materials for financial results
Fiscal Period Covered	Fiscal year ended June 2025
Net Sales	¥1,455 million (YoY +8.1%)
Operating profit	¥249 million (YoY +13.3%)
Ordinary income	¥240 million (YoY -0.2%)
Net income	¥256 million (YoY +5.4%)
Full-year earnings forecast	Net Sales ¥1,600 million / Operating profit ¥300 million / Ordinary income ¥300 million / Profit attributable to owners of the parent ¥260 million / Dividend per share ¥18
Segment results	Advanced research and development support business Net Sales Fiscal year ended June 2024 ¥1,186 million / Fiscal year ended June 2025 ¥1,143 million / Change in amount ¥-43 million / Cost Fiscal year ended June 2024 ¥876 million / Fiscal year ended June 2025 ¥958 million / Change in amount ¥82 million / Profit Fiscal year ended June 2024 ¥310 million / Fiscal year ended June 2025 ¥184 million / Change in amount ¥-126 million / Healthcare solutions business Net Sales Fiscal year ended June 2024 ¥158 million / Fiscal year ended June 2025 ¥311 million / Change in amount ¥153 million / Cost Fiscal year ended June 2024 ¥249 million / Fiscal year ended June 2025 ¥247 million / Change in amount ¥-2 million / Profit Fiscal year ended June 2024 ¥-90 million / Fiscal year ended June 2025 ¥64 million / Change in amount ¥155 million
Breakdown of Factors Affecting the Change	先端研究開発支援事業利益売上減少、売上減少に伴う原価減少、バイオものづくり支援サービスへの研究開発投資、人件費増加、貸倒引当 / ヘルスケア・ソリューション事業利益機能性素材開発包括支援サービス・皮膚ガス測定の売上増加、売上増加に伴う原価増加、研究開発投資の先端研究開発支援事業へのシフト / Consolidated operating profit 売上総利益増加額 ¥52 million
Key KPIs	12期連続増収 Yes / 5期連続営業増益 Yes / 新サービス受注 ¥13 million / Overseas business revenue -56 % / ROE Fiscal year ended June 2025 13.6 % / Year on year against the same period last year Not disclosed / WACC Fiscal year ended June 2025 3-5% / Year on year against the same period last year Down / Cost of shareholders’ equity Fiscal year ended June 2025 4-6% / Year on year against the same period last year Down / PBR Fiscal year ended June 2025 2.4 times / Year on year against the same period last year Not disclosed / PER Fiscal year ended June 2025 17.5 times / Year on year against the same period last year Not disclosed
Number of employees	Number of Employees 62 People / 博士 11 People / Reference date June 2025
Medium-term management plan targets	Net Sales Fiscal year ending June 2026 ¥1,600 million / Operating profit Fiscal year ending June 2026 ¥300 million / Ordinary income Fiscal year ending June 2026 ¥300 million / Profit attributable to owners of the parent Fiscal year ending June 2026 ¥260 million
Financial targets	ROE target 中長期的に15%以上 / Actual ROE 2025年6月期13.6%
Annual Dividend	Fiscal year ended June 2025 ¥15 / Forecast for the fiscal year ending June 2026 ¥18
Payout ratio	2026年6月期40%程度
Acquisition of treasury shares	実施中の自社株購入結果および中間決算の状況を踏まえ、自社株式取得を検討
Capital expenditures	5 億円（M&A・設備投資などの戦略投資資金）
New initiatives	Segment integration, バイオものづくり支援サービスの開始・早期立ち上げ, ペプチドスキャンアドバンスト、糖分析オプションの発売開始, 自社株式取得の検討

Items this document does not state (13)

Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

国内アカデミア・食品分野で大型受注が増加した一方、欧米では不透明感の高まりや政府支出削減、薬価引下げ対応によりライフサイエンス研究開発需要が低迷した。ヘルスケア・ソリューション事業では、食品・製薬・化学企業向けの機能性素材開発支援サービスと皮膚ガス測定が増加した。営業利益については、売上総利益が52百万円増加した一方、バイオものづくり支援サービスへの研究開発投資、人件費増加、貸倒引当などが影響した。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.